TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Subjects with a histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC).~2. Locally advanced and/or metastatic non-small cell lung cancer (NSCLC) (Stage IIIB/IV).~3. Subjects with at least one measurable tumor lesion by Response Evaluation Criteria In Solid Tumors (RECIST).~4. Subjects with Performance Status (PS) 0-1.~5. Subjects with adequate organ function.~Exclusion criteria:~1. Subjects who have ever received the following therapy for non-small cell lung cancer (NSCLC):~   1. Chemotherapy~  2. Biological or immunotherapies~  3. Surgery for primary focus~  4. The radiation therapy for primary focus~2. Subjects with the severe complications or disease history.~3. Subjects with brain metastasis accompanying clinical symptoms or requiring treatment.~4. Subjects with simultaneous or metachronous cancers.~5. Subjects who cannot take oral medication.~6. Subjects who are using drugs that strongly inhibit or induce cytochrome P450 (CYP) 3A4.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- E7080 (Dose Escalation Cohort) (Type: EXPERIMENTAL): This will be a dose-escalation evaluation of 12-18 participants to determine the maximum tolerated dose of E7080 in combination with paclitaxel and carboplatin.
- E7080 (Expansion Cohort) (Type: EXPERIMENTAL): Dosage of E7080 for Expansion Cohort will be determined based on the maximum tolerated dose in the Dose-Escalation Cohort.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Nebulised Hypertonic Saline (3%) Among Children With Bronchiolitis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 6 weeks to 24 Months.~* First episode of wheezing~* Fever, cough and watery nasal discharge~Exclusion Criteria :~* Any underlying cardiovascular disease.~* Prior wheezing.~* Clinical Severity Score \> 9.~* Atopic dermatitis, allergic rhinitis or asthma.~* Oxygen saturation (SpO2) \<85% on room air.~* Obtunded consciousness.~* Previous treatment with bronchodilators within 4 hours.~* Any steroid therapy within 48 Hours.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 2 Years
- Healthy Volunteers: f

Study Arms:
- Standard Treatment (Type: PLACEBO_COMPARATOR): L-Epinephrine and Normal Saline (0.9%)
- Study Treatment (Type: ACTIVE_COMPARATOR): L-Epinephrine and Hypertonic Saline (3%)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed diagnosis of 1 of the following:~  * Acute myelogenous leukemia (AML), meeting the following criteria:~    * In first relapse after first treatment-induced complete remission (CR) (closed to accrual as of 06/09/05)~      * Duration of first CR less than 12 months~     * No prior treatment for first relapse except hydroxyurea~   * FAB type M0, M1, M2, M4-7~   * No acute promyelocytic leukemia~   * No prior treatment with a standard induction regimen containing cytotoxic agents\* (for patients 60 years of age or older)~ * High-risk myelodysplasia, meeting the following criteria:~    * 60 years of age and over~   * No prior cytotoxic chemotherapy\* except hydroxyurea~   * Prior gemtuzumab ozogamicin allowed~   * High risk defined as International Prognostic Scoring System score ≥ 1.5, defined by cytogenetics, % marrow blasts, and lineage cytopenias NOTE: \*Prior low-dose, single-agent cytarabine, decitabine, or azacitidine not considered prior cytotoxic chemotherapy~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* ECOG 0-2~Life expectancy~* Not specified~Hematopoietic~* Not specified~Hepatic~* Bilirubin ≤ 2.0 mg/dL~* ALT or AST ≤ 5 times upper limit of normal~* Chronic hepatitis allowed~Renal~* Creatinine ≤ 2.0 mg/dL~Cardiovascular~* No myocardial infarction within the past 3 months~* No symptomatic coronary artery disease~* No uncontrolled arrhythmias~* No uncontrolled congestive heart failure~* No other active heart disease~Other~* No uncontrolled active infection~* Not pregnant or nursing~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Up to 4 leukapheresis procedures allowed during the first 15 days of study treatment~Chemotherapy~* See Disease Characteristics~* Concurrent additional hydroxyurea (maximum dose of 5 g daily for up to 4 days) allowed between days 4 and 15 of each study course to control elevated blast levels~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* Not specified~Other~* Recovered from all prior therapy~* At least 72 hours since prior anti-leukemic treatment with a non-cytotoxic agent~* No concurrent disulfiram (Antabuse)~* No other concurrent anticancer drugs except anagrelide within the first 15 days of study treatment to control elevated platelet counts~* No other concurrent treatment for leukemia, except hydroxyurea used during study treatment~* No other concurrent investigational drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Premenopausal, estrogen receptor positive women, aged 20 years and over, with operable and measurable breast cancer who have provided written informed consent~Exclusion Criteria:~* Medical history of chemotherapy or endocrine therapy for breast cancer, or with treatment history of radiotherapy. Unwillingness to stop taking any drug known to affect sex hormone status (including hormone replacement therapy (HRT).

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Tamoxifen
- 2 (Type: EXPERIMENTAL): Anastrazole (Arimidex)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: IMPAACT 2002: Cognitive Behavioral Therapy and Medication Management for Treatment of Depression in US Youth With HIV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Receiving mental health or HIV-related care at participating US IMPAACT site~* Confirmed HIV-1 Infection~* Aware of his or her HIV infection~* Per clinician assessment, primary diagnosis of nonpsychotic depression, including Major Depressive Disorder, Depression Not Otherwise Specified (NOS), or Dysthymia, as defined by Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV or DSM-V criteria~* Current depressive symptoms that warrant intervention as determined by a score of ≥ 11 on the Quick Inventory of Depressive Symptomatology - Clinician (QIDS-C)~* Able to communicate in spoken and written English~* Able and willing to provide written informed assent/consent and able to obtain written parental or guardian permission (if required, as specified in site standard operating procedure (SOP), by State law, and/or Institutional Review Board (IRB) policy) to be screened for and to enroll in IMPAACT 2002~Exclusion Criteria:~* Known or self-reported history of any psychotic disorder and/or bipolar I or II disorder~* Severe disorders (more than 6 symptoms) based on DSM-V criteria related to alcohol, cannabis or other substances; or those with moderate symptoms (4 or 5 symptoms) who are also currently experiencing withdrawal or dependence symptoms; within the past month prior to enrollment~* Per clinician assessment at screening, depression and/or suicidal ideation requiring more intensive treatment than the study provides or at immediate risk of being a danger to themselves or others~* Per participant report at screening, intends to relocate away from the study site during study participation~* Currently in therapy with a non-study provider, unless willing to switch to a study-trained provider~* Has any other condition that, in the opinion of the Investigator of Record (IoR)/designee, would preclude informed assent/consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 24 Years
- Healthy Volunteers: f

Study Arms:
- COMB-R (Type: EXPERIMENTAL): Health and Wellness Cognitive Behavioral Therapy and Medication Management (COMB-R) intervention
- Enhanced Standard of Care (Type: ACTIVE_COMPARATOR): Enhanced Standard of Care (ESC)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 20 to 80~* Hematopoietic WBC ≥ 4,000/mm\^3 Platelet ≥ 100,000/mm\^3~* Hepatic AST and ALT ≤ 2.5 times upper limit of normal(ULN) Total bilirubin ≤ 1.5 mg/dL~* Renal Creatinine ≤ULN~Exclusion Criteria:~* Prior anticancer treatment

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): TS-1 (S-1)
- 2 (Type: OTHER): Surgery alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study to Evaluate the Pharmacokinetics of BAT1806 vs Actemra® in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Signed the Inform Consent Form and fully understood the trial conduction, procedure and potential adverse reactions before entering the trial;~* Willing and able to follow the visits, treatments specified in this study;~* Subjects (including their partners) who are willing to refrain from pregnancy, sperm donation and take effective contraceptive method in the future 6 months (i.e. 6 months after study medication), see Appendix 4 for specific contraceptive methods;~* Healthy male subjects at age of 18-55 years (inclusive for both);~* BMI between 18-28 kg/m2 (inclusive for both) and body weight between 55-85 kg (inclusive for both);~* Normal physical examinations results or abnormality without clinical significance.~Exclusion Criteria:~* Daily smoking amount of \>5 cigarettes within 3 months prior to the trial;~* Any current or history of severe allergic reaction to foods or drugs and History of allergy to tocilizumab or severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies.~* Having a history of alcoholism (14 units of alcohol per week: 1 unit= 285 mL beer, or 25 mL spirit, or 125 mL wine);~* Having donated blood or loss of massive blood (\> 450 mL) within 3 months prior to screening, or planning to donate blood or to receive surgery during the study;~* Prior use of prescription medication, over-the-counter drugs, any vitamin products or herbs within 28 days before screening;~* Having significant changes in diet and exercise habits within 2 weeks before screening or from screening to dose;~* Having any diseases that increase the risk of bleeding, such as hemorrhoids with bleeding symptoms, acute gastritis or gastric and duodenal ulcers;~* Color Doppler echocardiography abnormalities with clinical significance;~* Having clinically significant laboratory abnormalities or other clinically indicated diseases (including but not limited to gastrointestinal, renal, liver, neurological, hematological, endocrine, tumor, lung, immune, mental or cardiovascular diseases);~* Ineligible subjects based on investigator's judgement.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- BAT1806 injection (Type: EXPERIMENTAL): BAT1806 injection: 4 mg/kg, intravenous infusion over 60 min
- Actemra(EU-licensed) (Type: ACTIVE_COMPARATOR): Actemra(EU-licensed): 4 mg/kg, intravenous infusion over 60 min
- Actemra(US-licensed) (Type: ACTIVE_COMPARATOR): Actemra(US-licensed): 4 mg/kg, intravenous infusion over 60 min

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Tacrolimus in Korean Nephropathy Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with IgA nephropathy confirmed by renal biopsy~* Serum creatinine measurement ≤1.5mg/ml or MDRD estimated GFR ≥ 45ml/min/1.73m2 (MDRD: Modification of Diet in Renal Disorder)~* UACR level between 0.3 and 3.0~* Blood pressure measurements \< 130/80mmHg~Exclusion Criteria:~* Use of immunosuppressants for more than two weeks within last one month~* Concomitant use of ACE inhibitor, ARB, steroids or immunosuppressant, NDHP-CCB, diuretics, omega-3 fatty acids and its analogue \& additional dietary to treat igA nephropathy (ACE: Angiotensin Converting Enzyme, ARB: Angiotensin Receptor Blocker, NDHP-CCB: Non-dihydropyridine-type Calcium Channel Blocker~* Pregnant or breast-feeding patients. Patients who plan to bear children or breast-feed during the study and within 6 month after completion of study~* Hypersensitivity to the investigational drug or macrolide agents~* Use of potassium-sparing diuretics~* Persistence of liver function abnormality more than 1 month or presence of acute active hepatitis~* Other investigational drug within last 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Tacrolimus group (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: None
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Receipt of Menactra vaccine during the study period.~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Menactra Vaccine Recipients (Type: None): Participants who received Menactra vaccine as part of routine medical care during the study period in Kaiser Permanente.
- Age-Matched Control (Type: None): Each individual receiving Menactra vaccine served as their own control for evaluation of acute (Days 0-30) events (short-term surveillance). For the 6-month (long-term) surveillance, for each person receiving Menactra vaccine, a control matched on age (± 1 year), sex, and month of vaccination was selected who received a received tetanus and diphtheria toxoids (Td), hepatitis A, hepatitis B, or hepatitis A/hepatitis B combination vaccine as part of routine medical care during the same month 1 year earlier in Kaiser Permanente

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Renal Impairment Study for PF-04965842

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Breath alcohol test at Screening and Day -1 must be negative.~* Body mass index (BMI) of ≥ 17.5 to ≤ 40.0 kg/m2; and a total body weight \>50 kg (110 lb).~Additional inclusion criteria for subjects with renal impairment:~* Meet the following eGFR criteria during the screening period based on the MDRD equation:~  * Severe renal impairment: eGFR \<30 mL/min, but not requiring hemodialysis.~ * Moderate renal impairment (Part 2 only): eGFR ≥30 mL/min and \<60 mL/min.~* Any form of renal impairment except acute nephritic syndrome (subjects with history of previous nephritic syndrome but in remission can be included).~* Stable concomitant drug regimen.~Exclusion Criteria:~* Renal transplant recipients.~* Urinary incontinence without catheterization.~* Subjects with clinically significant infections within the past 3 months (for example, those requiring hospitalization, or as judged by the Investigator), evidence of any infection (including influenza) within the past 7 days prior to baseline, history of disseminated herpes simplex infection or recurrent or disseminated herpes zoster.~* Subjects with a malignancy or with a history of malignancy, with the exception of adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.~* History of or current positive results for human immunodeficiency virus, Hepatitis B, Hepatitis C.~Additional exclusion criteria for subjects with renal impairment:~* Subjects requiring hemodialysis and peritoneal dialysis.~* Screening BP ≥ 180 mm Hg (systolic) or ≥ 110 mm Hg (diastolic).~* Screening supine 12-lead ECG demonstrating QTcF \>470 msec or a QRS interval \>120 msec.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- PF-04965842 (Type: EXPERIMENTAL): PF 04965842 is an oral selevtive janus kinase (JAK) 1 inhibitor

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fractional Dose Tetravalent A, C, Y, W135 Meningococcal Polysaccharide Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Volunteers should not be suffering of severe chronic disease or a known congenital or acquired immunodeficiency. A medical exam will be performed by a medical doctor before inclusion.~* Volunteers must be living in the Mbarara district and within 15 km from the site of immunization. Volunteers should be residents of the chosen site and should express no plan of moving from this area during the study period.~* Volunteers must be available for follow-up for the duration of the study (minimum of 24 months).~Exclusion Criteria:~* Volunteers with severe chronic disease or with a general condition requiring hospital admission.~* Volunteers with a known congenital or acquired immunodeficiency (e.g. HIV). Diagnosis will be presumptive based on the medical background and the clinical examination. No serological HIV testing will be performed.~* Evidence of any concomitant infection at the time of presentation (including rashes other than scabies; ear, nose or throat infections; and abnormal respiratory system examination).~* The patient has any other underlying diseases that compromise the diagnosis and the evaluation of the response to the study medication.~* History of serious adverse reactions to vaccines such as anaphylaxis or related symptoms such as hives, respiratory difficulty, angioedema and abdominal pain.~* Malnutrition: The nutritional assessment of children aged 24-59 months, a weight-for-height (W/H) index, will be calculated. This index is expressed in standard deviations of a normalised distribution of a reference population 38 (National Centre for Health Statistics, USA). Children under 5 years old with a Z-score inferior to -2 will be excluded. For children over 5 or adults, the clinical examination will be considered.~* Pregnant women and lactating women are not eligible for this trial. All women of child-bearing age must provide a urine sample for pregnancy testing before inclusion and, for sub-group b, before the second vaccine injection.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 20 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete